ZNF566 Inhibitors
Chemical inhibitors of ZNF566 function by modulating various cellular signaling pathways that ultimately lead to changes in the activity of this protein. PD 98059, U0126, and SL327 are all inhibitors targeting the Mitogen-activated protein kinase kinase (MEK), which is a part of the ERK pathway. By inhibiting MEK, these chemicals impede the phosphorylation and activation of ERK, a kinase that can regulate the activity of various transcription factors, possibly including ZNF566. Similarly, BIX 02189 inhibits the ERK5 pathway by selectively targeting MEK5, which could lead to a decrease in ZNF566 activity if it is regulated by this specific pathway.
Other compounds like LY294002 and Wortmannin achieve inhibition by targeting the phosphoinositide 3-kinases (PI3K) pathway. They prevent the activation of Akt, a kinase that plays a pivotal role in cell survival and metabolism, which can influence the regulation of ZNF566. SB203580 and SP600125 interfere with the p38 MAP kinase and c-Jun N-terminal kinase (JNK) pathways, respectively. SB203580's inhibition of p38 MAP kinase and SP600125's targeting of JNK can alter the transcriptional regulation of ZNF566, assuming there is a regulatory relationship. Rapamycin exerts its effects by inhibiting the mammalian target of rapamycin (mTOR), a central player in cell growth and proliferation, and this could lead to a reduction in ZNF566 activity. PP2 focuses on Src family kinases, and GF 109203X targets protein kinase C (PKC), both of which are involved in a multitude of signaling pathways that can affect transcription and, by extension, the function of ZNF566. Lastly, Y-27632, a Rho-associated protein kinase (ROCK) inhibitor, could lead to changes in the transcriptional activity of ZNF566 by modulating the actin cytoskeleton and consequently the transcriptional machinery within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a selective inhibitor of Mitogen-activated protein kinase kinase (MEK), which leads to the inhibition of the Extracellular signal-Regulated Kinase (ERK) pathway. Since ZNF566 is a zinc finger protein that may be regulated by the ERK pathway, inhibition of this pathway by PD 98059 can result in decreased activity of ZNF566. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor, which suppresses Akt phosphorylation and the downstream signaling pathway. ZNF566 function can be inhibited as the PI3K/Akt pathway is involved in the regulation of numerous proteins including zinc finger proteins. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a potent inhibitor of p38 MAP kinase, which is involved in regulating the activity of multiple transcription factors. Inhibition of p38 MAP kinase by SB203580 can inhibit the functional activity of ZNF566 if ZNF566 is downstream of p38 MAP kinase signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is an inhibitor of Rho-associated protein kinase (ROCK), which plays a significant role in regulating transcription through modulation of the actin cytoskeleton. Inhibition of ROCK by Y-27632 can lead to reduced functional activity of ZNF566 by altering the transcriptional regulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which affects transcription factor activity and gene expression. Inhibition of JNK by SP600125 can decrease the functional activity of ZNF566 if ZNF566 activity is JNK-dependent. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 selectively inhibits MEK1 and MEK2, which are involved in the ERK signaling pathway. The inhibition of these kinases can lead to reduced activity of ZNF566 if it is regulated through the ERK pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K, which blocks the PI3K/Akt pathway. Since this pathway can regulate a variety of proteins, including zinc finger proteins, inhibition by Wortmannin can lead to decreased functional activity of ZNF566. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an inhibitor of mammalian target of rapamycin (mTOR), which is a central regulator of cell growth and proliferation. Inhibition of mTOR by Rapamycin can lead to a reduction in ZNF566 activity by affecting its synthesis or regulatory pathways. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases, which are associated with various signaling pathways that regulate transcription. Inhibition of these kinases by PP2 can lead to reduced activity of ZNF566 by affecting signaling pathways that regulate its function. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
GF 109203X is a potent inhibitor of protein kinase C (PKC), which is involved in a wide range of cellular functions, including transcriptional regulation. Inhibition of PKC by GF 109203X can lead to decreased activity of ZNF566 through altered transcriptional regulation. | ||||||